Roderick Tze Ian Wong
DirectorDr. Roderick Tze Ian Wong, M.B.A., M.D., also known as Rod, serves as Director From June 2026 and served as Chairman of the Board of Rocket Pharmaceuticals, Inc. from January 2018 until June 2026. He is the Managing Director, Managing Partner and Chief Investment Officer at RTW Investments LP. He is Chairman and Board Executive Director of Corxel Pharmaceuticals (Shanghai) Co., Ltd., Corxel Pharmaceuticals, Inc. and Corxel Pharmaceuticals Limited. He has experience as a life sciences Fund Manager. Prior to this, from March 2005 to January 2009, He was employed at Davidson Kempner Capital Management LLC. He was a Managing Director and the Portfolio Manager for the Davidson Kempner Healthcare Funds. He held various healthcare investment and healthcare research roles at SAC Capital Advisors and Cowen & Company. He started managing a healthcare book in 2005. He is a Healthcare Analyst at Sigma Capital Management, LLC. He researched biotechnology companies at Cowen Group inc., where he is a Chief Executive Officer. Mr. Wong has been a Director of Attune Pharmaceuticals, Inc. since June 2018. Athira Pharma and C4 Therapeutics, where he serves as an observer to the Board of Directors. He also serves on the boards of Tenaya Therapeutics. He has been a Director of Ji Xing Pharmaceuticals since 2019 and NiKang Therapeutics, Inc. since September 14, 2020. He is a Director at RXi Pharmaceuticals Corporation. He was a Director of Penwest Pharmaceuticals Co. until 2010. He is Adjunct Assistant Professor at the New York University Stern Business School. He has completed medical training. He simultaneously received an MD from the University of Pennsylvania Medical School and an MBA from Harvard Business School and graduated Phi Beta Kappa with a BS in Economics from Duke University.
Positions
- Company NameRocket Pharmaceuticals, Inc.Stock CodeRCKTPositionDirectorColleagues
- GDGaurav D. ShahCEO & Director
- PMPeter M. FongIndependent Chairman of the Board
- MLMartin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer
- CSChristopher StevensChief Operating Officer
- JMJoseph ManhedePrincipal Accounting Officer
- JSJonathan SchwartzChief Science & Gene Therapy Officer
- CBCarsten BoessIndependent Director
- DPDavid P. SouthwellIndependent Director
